Measurement of Lipoprotein-Associated Phospholipase A2 by Use of 3 Different Methods: Exploration of Discordance between ELISA and Activity Assays

Topbaş, Celalettin; Swick, Alan R.; Razavi, Morteza; Anderson, N. Leigh; Pearson, Terry W.; Bystrom, Cory

doi:10.1373/clinchem.2017.279752

Cited by 27 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and potentially much more difficult if one is to avoid using separate calibrators for each assay (e.g., 3N calibrators in the present case, which would occupy 3 x 27 = 81 samples of each 96-well sample plate). Thus while a conventional mass calibration approach is possible for SISCAPA panels (using methods previously demonstrated for a number of individual clinical SISCAPA assays [14,15,58]), a simpler alternative, based on the labeled-peptide internal standards used in SISCAPA and other MS methods, would be highly desirable. Quantitative MS-based assays use measured quantities of a stable isotope labeled version of each peptide (SIS) as internal standards and thus provide readouts directly in fmol of target peptide.…”

Section: Interpreting Dbs Results: Normalization and Personalizationmentioning

confidence: 99%

Multiplexed measurement of protein biomarkers in high-frequency longitudinal dried blood spot (DBS) samples: characterization of inflammatory responses

Nl¹,

Razavi²,

Me³

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

A detailed understanding of changes in blood protein biomarkers occuring in individuals over time would enable truly personalized approaches to health and disease monitoring. Such measurements could reveal smaller, earlier departures from normal baseline levels of biomarkers thus allowing better disease detection and treatment monitoring. Current practice, however, generally involves infrequent, sporadic biomarker testing, and this undersampling likely fails to capture important biological phenomena. Here we report the use of a robust multiplex immunomass spectrometric method (SISCAPA) to measure a panel of clinically-relevant proteins in a unique collection of 1,522 dried blood spots collected longitudinally by 8 individuals over periods of up to 9 years, with daily sampling during some intervals. Analytical workflow CVs of 2-6% for most assays were achieved by normalizing DBS plasma volume using a set of 3 minimally varying proteins, facilitating temporal analysis of both high-and low-amplitude biomarker changes compared to personalized baselines. The biomarkers included a panel of 9 positive and 5 negative acute phase response (inflammatory) proteins, allowing longitudinal analysis of inflammation markers associated with major and minor infections, influenza vaccination, recovery from hip-replacement surgery and Crohn's disease. The results illustrate complex time-dependent "biomarker trajectories" on multiple timescales and provide a basis for detailed personalized models of inflammation dynamics. The striking stability of most biomarker protein levels over time, combined with the convenience of self-sampling and low cost of multiplexed measurements using mass spectrometry, provide a new window into the temporal dynamics of disease processes. The extensive results obtained using this high throughput approach offer a new source of precision biomarker 'big data' amenable to machine learning approaches and application to more personalized health monitoring.

show abstract

Section: Interpreting Dbs Results: Normalization and Personalizationmentioning

confidence: 99%

Multiplexed measurement of protein biomarkers in high-frequency longitudinal dried blood spot (DBS) samples: characterization of inflammatory responses

Nl¹,

Razavi²,

Me³

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…First, ELISA, the most common method of detecting level of Lp-PLA2 was used in our study. However, this level might change when a different measurement method is used [35]. Therefore, one of the key issues needs to be addressed is the standardization of Lp-PLA2 measurement method.…”

Section: Discussionmentioning

confidence: 99%

Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?

et al. 2020

View full text Add to dashboard Cite

Background: Inflammation has been believed to be related to the development of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH). A potential biomarker for vascular inflammation that is well recognized is the lipoprotein-associated phospholipase A2 (Lp-PLA2). However, whether Lp-PLA2 can predict the occurrence of symptomatic cerebral vasospasm (SCV) in aSAH patients is still unknown. Thus, this study aimed to assess the value of Lp-PLA2 for predicting SCV in patients with aSAH. Methods: Between March 2017 and April 2018, we evaluated 128 consecutive aSAH patients who were admitted in the First Affiliated Hospital of Fujian Medical University. Their Lp-PLA2 level was obtained within 24 h of the initial bleeding. Factors might be related to SCV were analyzed. Results: Compared to patients without SCV, those with SCV (9.4%, 12/128) had significantly higher Lp-PLA2 level. Multivariate logistic analysis revealed that worse modified Fisher grade (OR = 10.08, 95% CI = 2.04-49.86, P = 0.005) and higher Lp-PLA2 level (OR = 6.66, 95% CI = 1.33-3.30, P = 0.021) were significantly associated with SCV, even after adjustment for confounders. Based on the best threshold, Lp-PLA2 had a sensitivity of 83.3% and a specificity of 51.7% for predicting SCV, as shown by the receiver operating characteristic curve analysis. In the poor World Federation of Neurosurgical Societies grade patient subgroup , patients with Lp-PLA2 > 200 μg/L had significantly higher SCV rate than that of patients having Lp-PLA2 ≤ 200 μg/L. Conclusion: The admission Lp-PLA2 level might be a helpful predictor for SCV in aSAH.

show abstract

“…The knowledge of the absolute concentration of uAFM in healthy volunteers and diseased patients is still limited. ELISA is currently the most common method for measuring the concentration of a target protein in biological samples, with advantages including low cost and widespread application [38]. It is the first time to determine the absolute concentration of uAFM by ELISA, which will make the clinical routine application of uAFM possible.…”

Section: Discussionmentioning

confidence: 99%

Urine Afamin and Afamin–Creatinine Ratio as Biomarkers for Kidney Injury

Pang

Duan

et al. 2018

Biomark. Med.

View full text Add to dashboard Cite

Aim: The aim of this study was to evaluate the urine afamin (uAFM) and afamin–creatinine ratio (AfCR) levels in patients with glomerulonephritis. Patients & methods: We determined uAFM and AfCR of 247 healthy volunteers and 129 biopsy-proven glomerulonephritis patients. Results: Analytical evaluation study revealed the assay is a reliable and robust test for measuring uAFM. For reference intervals, uAFM and AfCR values were different significantly between males and females. uAFM and AfCR levels were significantly increased in patients with primary membranous nephropathy, IgA nephropathy and minimal change disease compared with healthy volunteers. uAFM and AfCR were positively correlated with urine albumin and albumin-creatinine ratio, respectively. Conclusion: Our study suggested that uAFM and AfCR may be attractive biomarkers for kidney injury.

show abstract

Measurement of Lipoprotein-Associated Phospholipase A2 by Use of 3 Different Methods: Exploration of Discordance between ELISA and Activity Assays

Cited by 27 publications

References 25 publications

Multiplexed measurement of protein biomarkers in high-frequency longitudinal dried blood spot (DBS) samples: characterization of inflammatory responses

Multiplexed measurement of protein biomarkers in high-frequency longitudinal dried blood spot (DBS) samples: characterization of inflammatory responses

Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?

Urine Afamin and Afamin–Creatinine Ratio as Biomarkers for Kidney Injury

Contact Info

Product

Resources

About